C
24.60
0.06 (0.24%)
| 前收盘价格 | 24.54 |
| 收盘价格 | 24.58 |
| 成交量 | 152,777 |
| 平均成交量 (3个月) | 1,066,605 |
| 市值 | 1,632,067,328 |
| 价格/销量 (P/S) | 149.31 |
| 股市价格/股市净资产 (P/B) | 2.07 |
| 52周波幅 | |
| 利润日期 | 24 Feb 2025 - 28 Feb 2025 |
| 营业利益率 (TTM) | -1,633.53% |
| 稀释每股收益 (EPS TTM) | -2.58 |
| 季度收入增长率 (YOY) | 110.30% |
| 总债务/股东权益 (D/E MRQ) | 0.39% |
| 流动比率 (MRQ) | 24.27 |
| 营业现金流 (OCF TTM) | -157.84 M |
| 杠杆自由现金流 (LFCF TTM) | -83.73 M |
| 资产报酬率 (ROA TTM) | -19.73% |
| 股东权益报酬率 (ROE TTM) | -29.84% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Celldex Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
1.4
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.0 |
| 平均 | 1.38 |
|
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.30% |
| 机构持股比例 | 108.05% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 80.00 (HC Wainwright & Co., 225.20%) | 购买 |
| 中 | 73.50 (198.78%) | |
| 低 | 67.00 (Cantor Fitzgerald, 172.36%) | 购买 |
| 平均值 | 73.50 (198.78%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 25.33 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Cantor Fitzgerald | 29 Jan 2025 | 67.00 (172.36%) | 购买 | 25.51 |
| 02 Jan 2025 | 67.00 (172.36%) | 购买 | 25.79 | |
| HC Wainwright & Co. | 20 Dec 2024 | 80.00 (225.20%) | 购买 | 25.14 |
| 19 Dec 2024 | 80.00 (225.20%) | 购买 | 25.38 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合